Please login to the form below

Not currently logged in
Email:
Password:

Almirall appoints Peter Guenter as its CEO

He joins from Sanofi where he was executive vice president

Peter GuenterAlmirall has appointed Peter Guenter as its new chief executive officer, succeeding Eduardo Sanchiz who leaves to spend more time dedicated to other interests.

Guenter joins from Sanofi, where he has worked for the past 22 years, most recently as executive vice president diabetes and cardiovascular global business unit.

He said: “I am excited and eager to join Almirall as CEO. The company has a clearly defined strategy, putting the patients and customers at the centre of everything we do.

“Together with my team, I am convinced we will be able to fully unlock the value of Almirall.”

He previously held many senior positions at Sanofi, including vice president Eastern Europe and Northern Europe, vice president business management and support, general manager, Germany, and senior vice president, Europe.

Jorge Gallardo, chairman of the board, Almirall, said: “I am particularly satisfied that we have been able to attract Peter to Almirall.

“He is a truly global leader and brings a wealth of experience in US, Europe, and emerging markets. I am convinced he will bring what is needed to develop Almirall to the next level.”

Sanchiz will hand over the leadership of Almirall to Guenter during September.

30th August 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics